Seagen Inc.

Seagen Inc.

Seagen Inc.

Overview
Date Founded

1998

Headquarters

21823-30th Drive SE,Bothell, WA 98021

Type of Company

Public

Employees (Worldwide)

1,605

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Contact Data
Trying to get in touch with decision makers at Seagen Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer & Chief Accounting Officer

General Counsel, Executive Vice President, Legal Affairs & Corporate Secretary

Chief Scientific Officer

Chief Technical Officer

Chief Medical Officer

Executive Vice President, Commercial US

Executive Vice President, Human Resources

Executive Vice President-Corporate Development

Executive Vice President, Corporate Strategy, Alliances & Communications

Board of Directors

Co-Founder at Seagen Inc.

Co-Founder at Baker Bros. Advisors LP

President & Chief Executive Officer at Atreca, Inc.

Co-Founder at Ascenta Therapeutics, Inc.

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Consultant at Aerie Pharmaceuticals, Inc.

Executive Chairman at Incarda Therapeutics, Inc.

President & Chief Executive Officer at Syros Pharmaceuticals, Inc.

Chief Executive Officer at Nura Bio

Paths to Seagen Inc.
Potential Connections via
Relationship Science
You
Seagen Inc.
Owners & Shareholders
Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Details Hidden

CRMC's International Investors division invests primarily in the stocks of large-cap growth-oriented companies across practically all sectors. Although they invest internationally, most of their investments are in the stocks of North American companies. They maintain an investment philosophy that is distinguished by four key beliefs: (1) solid research is fundamental to sound investment decisions; (2) investment decisions should not be made lightly; (3) a long-term approach; (4) the capital system.

Details Hidden

PRIMECAP Management aims to provide superior long-term investment results by utilizing fundamental research and bottom-up stock picking to construct portfolios. The firm looks for stocks that will outperform the market over a three to five-year horizon. PRIMECAP Management does not have a committee or small group that decides on whether or not to invest in an idea. Each portfolio manager makes an individual decision whether or not to invest in new ideas.

Recent Transactions
Details Hidden

Seagen Inc. issued USD Common Stock

Details Hidden

Seagen Inc. purchases Cascadian Therapeutics, Inc.

Details Hidden

Seagen Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onSeagen Inc. issued USD Common Stock

Underwriter

Advised onSeagen Inc. issued USD Common Stock

Underwriter

Advised onSeagen Inc. issued USD Common Stock

Underwriter

Advised onSeagen Inc. issued USD Common Stock

Legal Advisor

Advised onSeagen Inc. issued USD Common Stock

Head, Healthcare Investment Banking

Advised onSeagen Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Cooley LLP

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Key Stats and Financials As of 2019
Market Capitalization
$30.3B
Total Enterprise Value
$18.2B
Earnings Per Share
$-0.96
Revenue
$917M
Net Profit
$-159M
Total Equity
$1.88B
EBITDAMargin
-20.4%
Debt TEV
0x
TEVNet Income
-114.57x
Enterprise Value / Sales
19.83x
Total Debt
$77.1M
EBITDA
$-187M
Three Year Compounded Annual Growth Rate Of Revenue
29.91%
Non-Profit Donations & Grants
Investments
Details Hidden

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Investors
Details Hidden

Credit Agricole SA engages in the provision of banking and financial services. It operates through the following segments: French Retail Banking - Regional Banks, French Retail Banking - LCL, International Retail Banking, Savings Management & Insurance, Specialized Financial Services, Corporate & Investment Banking, and Corporate Centre. The French Retail Banking - Regional Banks segment provides banking and financial services for individual customers, farmers, small businesses, corporate and local authorities. The French Retail Banking - LCL segment offers asset management, insurance, and wealth management products. The International Retail Banking segment covers foreign subsidiaries and investments that are involved in retail banking. The Asset gathering segment offers: asset management activities; asset servicing for institutions; life insurance and personal insurance; property and casualty insurance; credit insurance activities; and private banking activities conducted mainly by CA Indosuez Private Banking and by Crédit Agricole subsidiaries. The Specialized Financial Services segment provides consumer financing services and specialized financial services such as factoring and leasing and this segment also handles the group subsidiaries which provides financial products and services to individual customers, small businesses, corporates and local authorities in France and abroad. The Large customers segment operates in capital markets, investment banking, and financing activities. The Corporate Center segment involves central body function, asset and liability management, and results of the private equity business and various companies of the group. The company was founded on November 5, 1894 and is headquartered in Montrouge, France.

Details Hidden

Entrepreneur in Residence at University of Washington

Details Hidden

Cascade Investment invests primarily in fixed-income securities. The firm employs a macroeconomic approach that focuses on interest and inflation rates, market trends and sector growth rates. They utilize a value-oriented equity investment approach that focuses on investments in stocks that are undervalued and under-followed as the result of negative trends in the market. The firm may short position and invests in commodities and private equity.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

University of Miami Schools & Student Services | Miami, FL

The University of Miami is a private research university in Coral Gables, Florida. As of 2019, the university enrolls 17,811 students in 12 separate colleges/schools, including the Leonard M. Miller School of Medicine in Miami's Health District, a law school on the main campus, and the Rosenstiel School of Marine and Atmospheric Science focused on the study of oceanography and atmospheric sciences on Virginia Key, with research facilities at the Richmond Facility in southern Miami-Dade County. The university offers 132 undergraduate, 148 master's, and 67 doctoral degree programs, of which 63 are research/scholarship and four professional areas of study. Over the years, the university's students have represented all 50 states and close to 150 foreign countries. With more than 16,000 full- and part-time faculty and staff, UM is a top 10 employer in Miami-Dade County. UM's main campus in Coral Gables has 239 acres and over 5.7 million square feet of buildings. Research is a component of each academic division, with UM attracting $358.9 million in sponsored research grants in FY 2019. UM offers a large library system with over 3.9 million volumes and exceptional holdings in Cuban heritage and music. UM also offers a wide range of student activities, including fraternities and sororities, a student newspaper and a radio station. UM's intercollegiate athletic teams, collectively known as the Miami Hurricanes, compete in Division I of the National Collegiate Athletic Association. UM's football team has won five national championships since 1983 and its baseball team has won four national championships since 1982.

Diversified Healthcare Trust Trusts & Funds | Newton, MA

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants. The SHOP segment manages senior living communities that offers short term and long term residential care, and other services for residents where it pay fees to the operator to manage the communities for its account. The company was founded on December 16, 1998 and is headquartered in Newton, MA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Seagen Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Seagen Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Seagen Inc..